Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brian Yang

Beijing-based Brian Yang is a senior writer in charge of overall China coverage within the APAC Pharma news team. A veteran journalist, he has written extensively on pharmaceutical R&D, regulatory affairs and market access for PharmAsia News. Brian’s intimate industry knowledge and in-depth analysis has won wide praise and helped secure exclusive interviews with top biopharma executives.
He has led a team of writers to provide industry-leading coverage on key issues such as multi-regional clinical trials, priority reviews and go-to-market strategies in a highly-dynamic and fast-changing market, with the on-the-ground coverage consistently ranked among the top-read in PharmAsia News.

Prior to joining Informa, Brian worked as a foreign affairs correspondent for two TV networks and web editor for an international radio station. Trilingual in Mandarin Chinese, English and Japanese, he obtained his BA degree from China and an MA degree from Japan.

Advertisement
Set Alert for Articles By Brian Yang

Latest From Brian Yang

Asia Executives To Watch: Pfizer Japan New President, Novo Nordisk China GM

Pfizer appoints new leadership in Japan amid sluggish growth. Top executive changes also made at Novo Nordisk and Stryker in China, Hutchison MediTech and Boston Scientific in the Asia Pacific.

Commercial Appointments

China Innovation Policy Reform Streamlines Trial Management

China's latest initiative to establish an innovation ecosystem replaces clinical trial site pre-certification with registration; also included are provisions allowing use of foreign data, strengthening data protection and providing conditional approvals of rare disease treatments.

China Clinical Trials

Mooncakes Under The Sun: Can China's ‘Name And Shame’ Rule Create Level Playing Field?

China's proposal to register all medical sales reps could lead to the eventual elimination of kickbacks to physicians. Experts say it's the first step towards creating a level compliance playground for multinational and domestic drug makers.

China Compliance

Focused China Local Strategy Remains Key Despite Country's Joining ICH – Executives

Top China executives from Pfizer, AstraZeneca, GSK share their views on growing in China amid lingering challenges despite regulatory progress.

China Regulation

Asia Executives To Watch: Takeda China GM; Wuxi NextCODE; Sosei

Takeda hires former Pfizer China executive as its new China GM; Wuxi NextCODE appoints its second COO in six months; Sosei appoints two VPs.

Appointments China

Zai Lab Soars On Nasdaq Debut

Shanghai-based drug developer Zai Lab shares jumped on its first day of public trading, reflecting the strong interest in drug development in China.

Financing China
See All
Advertisement
UsernamePublicRestriction

Register